Showing 61-70 of 3321 results for "".
How do barrier dysfunction proteins interact with immune dysregulation to sustain AD?
https://practicaldermatology.com/series/dermatology-hub-neuroimmune-network/how-do-barrier-dysfunction-proteins-interact-with-immune-dysregulation-to-sustain-ad/56736/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses whether barrier dysfunction drives inflammation and immune dysregulation, or vice versa, or both, in atopic dermatitis.Psoriasis 2020
https://practicaldermatology.com/topics/psoriasis/psoriasis-2020/19720/Bruce Strober, MD, PhD reviews the latest advances in psoriasis therapy, including anticipated breakthroughs in biologics, small molecule agents, and topicals.Sleep Disturbances and Psychological Burden of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/sleep-disturbances-and-psychological-burden-of-prurigo-nodularis/37182/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses the impact of itch from prurigo nodularis on quality of life through sleep disturbances and mental health effects.Sleep Disturbances and Psychological Burden of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/sleep-disturbances-and-psychological-burden-of-prurigo-nodularis/48790/Raj Chovatiya, MD, PhD, MSCI, FAAD, discusses the impact of itch from prurigo nodularis on quality of life through sleep disturbances and mental health effects.Noah Worcester 2024: Dr. Webster on Isotretinoin
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-webster-isotretinoin/24581/Guy Webster, MD, PhD, FAAD, summarizes his lecture on new developments in isotretinoin at the 2024 Noah Worcester Dermatological Society meeting.New Data on Oral Therapeutics for Psoriasis
https://practicaldermatology.com/conferences/maui-derm-hawaii-2026/new-data-on-oral-therapeutics-for-psoriasis/54643/Bruce Strober, MD, PhD, discusses key takeaways from the “Acne and Rosacea: Update 2026” session at Maui Derm Hawaii 2026.Novel PsO Drug Could Be 'Closest Perception of a Cure,' Dr. Strober Says at Maui Derm
https://practicaldermatology.com/programs/practical-dermatology/novel-pso-drug-could-be-closest-perception-of-a-cure-dr-strober-says-at-maui-derm/32922/A novel monoclonal antibody targeting IL-23 for the treatment of psoriasis offers an extended half-life that will be a key differentiator for patients, according to Bruce Strober, MD, PhD.Updates from the AAD Annual Meeting in San Diego
https://practicaldermatology.com/topics/practice-management/updates-from-the-aad-annual-meeting-in-san-diego/18332/From cosmetic interventions to therapeutic breakthroughs for common dermatoses, and new technologies for practice, the latest innovations take center stage at the 2018 Annual Meeting of the American Academy of Dermatology. Joel L. Cohen, MD; Yolanda Lenzy, MD, MPH; Junko Takeshita, MD, PhD, MSCE; anThe Landscape for Vitiligo: An Interview with Larry Green, MD
https://practicaldermatology.com/topics/pigmentary-disorders/the-landscape-for-vitiligo-an-interview-with-larry-green-md/24209/Practical Dermatology® Chief Medical Editor Neal Bhatia, MD, FAAD, talked with Larry Green, MD, a board-certified dermatologist in private practice in Rockville, Maryland, about the latest in vitiligo treatment and what practitioners can tell their patients about recent advances in treatment for thiPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 6
https://practicaldermatology.com/series/the-practical-dermatology-roundtable/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-6/32904/In the final installment of a six-part series, host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, recap the recommended protocol for treating generalized psoriasis treatment, starting from the initial diagnosis, as well as the safety of targeted